Rituximab in Addition to Autologous Transplantation With BEAM for Patients With Lymphoid Malignancies
Status:
Completed
Trial end date:
2012-06-01
Target enrollment:
Participant gender:
Summary
Cohort 1: Patients who are less than or equal to 65 years of age.
1. To determine the disease-free survival (DFS) in the 2 arms (standard dose versus high dose
rituximab)
Cohort 2: Patients who are older than 65 years of age
1. To determine the disease-free survival (DFS) in the 2 arms (standard dose versus high
dose rituximab)
2. To determine the treatment related mortality (TRM)